What a biotech should evaluate before engaging a contract CTM
Role scope, study context, decision authority, operating model, and transition risk all affect whether a CTM can contribute quickly.
Read the guide →Lampgen insights
Practical perspectives on oncology development, clinical operations, and the workforce decisions behind successful execution.
THE SIGNAL™ LENS
In selected analyses, Lampgen uses the SIGNAL™ framework to connect the evidence to a specific monitoring question. See how one observation becomes a question a study team can investigate.
Walk through a fictional exampleREGULATORY INTELLIGENCE
Search U.S. FDA oncology approvals, review the evidence, and create a sourced LinkedIn article brief. Selected records include a clinical operations takeaway and a related Lampgen resource.
Featured / Before your next staffing decision
Role scope, study context, decision authority, operating model, and transition risk all affect whether a CTM can contribute quickly.
Read the guide →Study phase, mechanism, biomarker strategy, site landscape, safety profile, and enrollment competition create different operating demands.
Read the guide →The correct answer depends on whether the gap is individual capacity, recurring functional ownership, or a broader delivery-model problem.
Read the guide →100 insights
Plan rare-cancer trial referral, testing, visits, and follow-up around named owners and documented participation barriers.
Read the insight →Plan oncology biomarker screening with clear specimen, laboratory-report, and eligibility-review handoffs and scoped monitoring responsibilities.
Read the insight →Define CTM scope, decision authority, study context, onboarding, and transition responsibilities before starting a contract search.
Read the insight →Evaluate oncology operating experience through phase, treatment model, site responsibilities, safety coordination, biomarkers, and decision ownership.
Read the insight →Compare an individual clinical operations capacity gap with recurring functional work before choosing how to resource an oncology study.
Read the insight →Spot five signs of a clinical operations capacity gap, from missed milestones and monitoring coverage to growing trial master file backlogs.
Read the insight →Translate biotech financing into a staffing plan for new studies, site activation, monitoring, vendor oversight, and trial expansion.
Read the insight →Evaluate Phase 1 oncology CTM and CRA readiness for dose escalation, evolving safety data, eligibility, and rapid protocol amendments.
Read the insight →Plan oncology trial staffing around enrollment, upcoming milestones, and monitoring risk before workload turns into a delivery problem.
Read the insight →Prepare clinical operations for cohort expansion, new sites, vendor changes, and pivotal trial planning after a positive oncology readout.
Read the insight →Evaluate oncology CRA staffing costs beyond hourly rates, including CTM oversight, unresolved site issues, and repeat monitoring work.
Read the insight →Plan for the shift in safety coordination, site monitoring, data review, and enrollment oversight after the first patient is dosed.
Read the insight →Compare sponsor and CRO perspectives on clinical trial oversight and clarify escalation, decision authority, and accountability.
Read the insight →Plan staffing, vendor coordination, data review, and trial documentation when a regulatory milestone compresses the development timeline.
Read the insight →Connect site findings to sponsor decisions with a documented action owner, cross-site review, and an effectiveness check using Lampgen’s SIGNAL framework.
Read the insight →Decide when a contract CTM or CRA can fill a trial capacity gap and when the work calls for a permanent clinical operations hire.
Read the insight →Define sponsor responsibilities, handoffs, staffing, and governance before a biotech partnership adds new clinical trial work.
Read the insight →Prepare system access, study documents, decision authority, and handoffs before a contract CRA or CTM starts.
Read the insight →Identify when trial starts, positive data, financing, and partnerships warrant a review of oncology clinical operations staffing.
Read the insight →Evaluate oncology CRA judgment using protocol-specific scenarios, escalation decisions, relevant role ownership, and follow-through.
Read the insight →Use six questions to review CTM workload, monitoring coverage, trial master file readiness, and backup staffing before the next milestone.
Read the insight →Founder Tommy Lampley explains how his oncology CRA and study management experience shaped Lampgen’s clinical operations staffing model.
Read the insight →When an oncology trial stops, a patient may already have tomorrow’s dose at home and next week’s visit on the calendar. Who calls them, and what instructions can that person give?
Read the insight →Lilly stopped the Alzheimer’s program after the Phase 2 results fell short of its threshold to continue.
Read the insight →What SELLAS’s Phase 3 REGAL topline means for AML maintenance, survival evidence, clinical trial follow-up and oncology monitoring responsibilities.
Read the insight →What the loss of U.S. measles elimination status means for vulnerable cancer patients, site preparedness, clinical trial continuity and oncology CRA responsibilities.
Read the insight →What LANT’s reported FDA Breakthrough Device designation means for human evidence, safe delivery, oncology trial readiness and CRA and CTM responsibilities.
Read the insight →What Virtuoso’s De Novo authorization means for bladder-lesion tissue quality, pathology traceability and oncology trials, with early VIABLE evidence and limits.
Read the insight →Plan sponsor decision ownership, CRA responsibilities, escalation and follow-up before a small biotech’s first oncology trial.
Read the insight →What Carteyva’s China reimbursement decision could mean for CAR-T access, referrals, manufacturing coordination, trial planning and clinical operations staffing.
Read the insight →Review new evidence on trial invitations, recruitment feedback and community engagement, plus NIH’s draft monitoring policy and implications for oncology sponsors.
Read the insight →What the All of Us drug-response genetics study means for representation, DPYD testing, clinical review and oncology trial operations.
Read the insight →How connected cancer datasets, reproducible findings and reliable trial records support responsible AI research—and which benefits still need evidence.
Read the insight →What a 25.5-million-cell basal ganglia atlas reveals about Parkinson’s and schizophrenia research, and the evidence still needed for human benefit.
Read the insight →What Rezolute’s preliminary Phase 3 upLIFT findings mean for tumor-related hypoglycemia, glucose-support endpoints and oncology trial operations.
Read the insight →What Pfizer’s up-to-$1.5-billion Blackstone funding agreement means for berobenatide development, monthly dosing evidence and clinical trial oversight.
Read the insight →Hemogenyx CAR-T delivery, Cardiff Phase 3 funding and Immuneering–Astellas biomarker studies lead Lampgen’s November 12, 2026 oncology briefing.
Read the insight →What the November 2026 ACS prostate screening update means for PSA testing, Black men’s health, diagnostic access and oncology trial teams.
Read the insight →How AURORA will test AI co-scientists in cancer discovery, what remains unproven, and what stronger findings could mean for oncology trial teams.
Read the insight →Why Lilly’s enrollment lead needs context: disease mix, primary-outcome follow-up, site-month denominators and practical implications for oncology trial teams.
Read the insight →Review the Optune Mya FDA decision, what the Phase 3 METIS brain metastases trial measured, and how trial teams can protect follow-up after treatment stops.
Read the insight →Pelacarsen lowered Lp(a) in Phase 3 Lp(a)HORIZON. See what the neutral cardiovascular outcomes mean for Amgen, Lilly, and clinical trial teams.
Read the insight →Phase 3 survodutide met its cardiovascular safety endpoint. See the gastrointestinal discontinuation rates and why more flexible dose escalation matters.
Read the insight →See what chatbot studies show about mental health referrals and symptoms, and how a trial could test whether more men complete a first visit.
Read the insight →What an AI-generated math proof can teach oncology trial teams about tracing monitoring alerts to source records and measuring missed deviations.
Read the insight →The FDA requires GLP-1 labels to warn of potential NAION risk. Review the trial and Sentinel evidence and what sponsors can do to prepare study sites.
Read the insight →QUILT-2.005 met its six-month complete response endpoint in BCG-naïve bladder cancer. See what the topline leaves open and how sites capture the endpoint.
Read the insight →What the Medicaid and ACA subsidy debate could mean for oncology trial access, and how sites can handle coverage changes before a visit is missed.
Read the insight →See how tumor grade and size shape recurrence risk in the monarchE nodal analysis and what oncology sites can do to document screening decisions.
Read the insight →See who qualifies for FDA-approved bepirovirsen, how B-Well measured functional cure, and what trial teams can do to protect off-treatment follow-up.
Read the insight →How oncology sites and monitors document sleep changes, reconcile medication timelines and give investigators the context to assess adverse events.
Read the insight →Compare ALTAIR, KRYSTAL-10, EVOKE-03, IMvigor011 and eight other reports on cancer biomarkers, trial endpoints, treatment decisions, and patient access.
Read the insight →Use a fictional pre-dose lab case and a three-part scoring rubric to assess how oncology CRAs verify, escalate, and follow up on potential safety issues.
Read the insight →A perfect-pitch case and the TRACK-TBI cohort show why brain injury studies need meaningful outcomes, well-timed assessments, and accessible follow-up.
Read the insight →What mitochondrial donation studies show, how to interpret fertility claims, and why IVF outcomes need age-specific live-birth rates and long-term follow-up.
Read the insight →Trace oncology trial scans from acquisition to central review and learn how to reconcile imaging assessments before database lock.
Read the insight →What the 2026 midterms mean for NIH appropriations, grant reviews, scientific continuity, oncology trial staffing and equitable research access.
Read the insight →A Nature Medicine atlas found more stromal tissue in younger patients’ microsatellite-stable colorectal tumors. See what future trials can test and how sites can prepare.
Read the insight →Explore preeclampsia treatment research targeting sFlt-1 and VGLL3, the limits of early-stage evidence, maternal–fetal safety and equitable trial access.
Read the insight →What nine post-Zolgensma tumor reports, two vector-integration findings, and the investigation mean for rare disease gene therapy safety, FDA warnings and long-term follow-up.
Read the insight →A 2026 study models PhRMA's $58.8 million search ad campaign. Explore PBM messaging, methodology limits, drug pricing policy and oncology patient access.
Read the insight →What AHEAD and SOKRATES found about learning an amyloid result before Alzheimer’s symptoms, and how trials can plan consent, disclosure and follow-up.
Read the insight →Compare the $97.41B clinical trial services forecast with the broader CRO market and see how oncology sponsors can use monitoring to resolve repeat site issues.
Read the insight →Merck targets 10+ oncology medicines by 2030. Explore 2026 ADC and cancer-vaccine trial milestones, oncology CRA staffing and patient access implications.
Read the insight →Pfizer cut seven development entries in November 2026. Explore PAH, GIPR and KRAS decisions and the responsibilities of oncology trial monitoring and closeout.
Read the insight →How China's 2026 investigator-initiated trial reforms affect gene therapy safety, rare-disease access, sponsor oversight and monitoring.
Read the insight →Read what FDA’s November 2026 final potency assurance guidance means for cell and gene therapy manufacturing, CAR-T site readiness, and CRA monitoring.
Read the insight →Twelve pharma and biotech updates, including what Genmab’s LiGeR-HN1 results mean for PD-L1 screening, oncology site activation and survival follow-up.
Read the insight →Moderna’s first profitable quarter in two years coincides with positive Phase 3 melanoma results. Explore how tissue adequacy and logistics could shape access.
Read the insight →Generate Biomedicines cut a CAR-T signaling domain by about 70%. See what the cell assays showed and what in vivo delivery studies need to establish.
Read the insight →Compare Wegovy pill and Foundayo prescriptions, Q3 sales and dosing routines. See what research teams can measure to assess access and treatment persistence.
Read the insight →How oncology trial teams can respond to an interrupted visit, protect safety follow-up and document which assessments can still be completed.
Read the insight →Explore late recurrence in HR-positive, HER2-negative early breast cancer, survival findings from monarchE and NATALEE, and what oncology trial teams can do to protect long-term follow-up.
Read the insight →Review the FDA’s accelerated approval of Rybrevant Faspro in previously treated head and neck cancer, the OrigAMI-4 evidence, and what Phase 3 OrigAMI-5 will test.
Read the insight →What Immunocore’s Phase 1/2 uveal melanoma data showed about survival and safety, and what the planned randomized trial can clarify.
Read the insight →Explore Lilly's recruiting PIKALO-2 tersolisib breast cancer trial, mutant-selective PI3Kα rationale, evidence limits and oncology site-readiness priorities.
Read the insight →Review Rasonque’s $197.6M launch, the RASolute 302 survival results and what the first-line RASolute 303 and 309 studies will ask of oncology sites.
Read the insight →Explore the six-program Boehringer–Sino oncology partnership, conditional deal economics, and implications for early-phase trial operations.
Read the insight →Understand FDA real-world evidence principles, AI model credibility, digital-twin limitations and the role of oncology trial data quality.
Read the insight →Read the evidence on Alzheimer's biomarker result disclosure, psychological experience and clinical trial implications.
Read the insight →Explore China's 2026 investigator-initiated trial safeguards, rare-disease access dilemmas and operational implications for sponsors and CROs.
Read the insight →Review A2 Bio’s early DENALI-1 CAR-T findings in solid tumors, their limitations, and the biomarker screening and monitoring work behind interpretable evidence.
Read the insight →Understand the denominator behind Lyell’s ronde-cel lymphoma response rates, safety findings, follow-up limits and implications for CAR-T trial operations.
Read the insight →Understand the MANGROVE Priority Review, the limits of its reported PFS result, and how ongoing oral treatment changes operational planning.
Read the insight →Understand camizestrant’s accelerated FDA approval, SERENA-6 results, evidence limitations and operational needs for ESR1-guided breast cancer care.
Read the insight →Review the disputed Madrigal Rezdiffra safety allegations, the company’s response, FDA labeling and implications for clinical trial safety oversight.
Read the insight →Understand CVS Health’s proposed 2028 split, retained Aetna–Caremark–specialty pharmacy integration, and what oncology teams should watch for patient access.
Read the insight →Learn how to review staffing continuity, critical backlogs and decision ownership alongside enrollment totals in oncology trials.
Read the insight →Explore the shift from individual site findings to study-wide decisions, escalation and verification when moving from CRA to CTM.
Read the insight →Connect FDA ADC clinical-pharmacology guidance to protocol-specific sampling, safety documentation and staff preparation.
Read the insight →Use five practical checks for investigational product, staffing, laboratory logistics, systems and first-visit coordination.
Read the insight →Separate clinical exclusions, screening logistics and operational delays before choosing how to address enrollment problems.
Read the insight →Understand how patient-reported outcomes complement tumor measures, and what site teams need for reliable collection.
Read the insight →Review travel, time away from work, caregiving and reimbursement timing as practical barriers to clinical trial participation.
Read the insight →Read the 2025 randomized AI-alert study accurately and use its limits to evaluate the complete trial enrollment workflow.
Read the insight →Use role-specific oncology scenarios to evaluate Senior CRA and CTM judgment, escalation and follow-through.
Read the insight →Review Insmed’s 12-month open-label TPIP findings in pulmonary arterial hypertension and what sites need for the PALM-PAH Phase 3 trial.
Read the insight →Review estimated drug acquisition costs across federally sponsored cancer trials and the implications for pharmacy readiness and trial supply.
Read the insight →Explore Novo Nordisk’s Q3 2026 GLP-1 growth, CagriSema trial results, and implications for clinical operations, patient access and evidence quality.
Read the insight →Review the zola-cel patient death disclosure, preliminary Breakfree-2 multiple sclerosis data, and implications for CAR-T trial safety and monitoring.
Read the insight →Lampgen content distinguishes reported facts from interpretation and connects scientific or regulatory developments to the practical demands they create for clinical teams.
AVAILABLE FOR NEW PARTNERSHIPS